Gilvetmab – For Veterinary Professionals

Merck Animal Health has conditional approval for a new cancer treatment. What you need to know:

Gilvetmab is a caninized monoclonal antibody against canine programmed cell death receptor-1
It is indicated for the treatment of dogs with mast cell tumors or melanomas

“*” indicates required fields

First Name*

Last Name*

Job Title*

Specialty*

Email Address*

Mobile Phone*

Business Name*

Address 1*

Address 2

Business State*

Business Zip*

Business Phone*

emailconsent

I am interested in receiving communications from Merck Animal Health and its subsidiaries on products, programs and scientific information. I can manage my communication preferences by clicking on the link at the bottom of my email at any time.

Comments

This field is for validation purposes and should be left unchanged.

INDICATIONS: For the treatment of dogs with mast cell tumors or melanomas. This product has demonstrated a reasonable expectation of efficacy and a preliminary safety profile in reducing the solid tumor burden in dogs with stage I, II, and III mast cell tumors or dogs with stage II and III melanomas. This product license is Conditional; safety, efficacy, and potency have not been fully evaluated. For more information regarding safety, see productdata.aphis.usda.gov. This product contains gilvetmab, a caninized monoclonal antibody against canine programmed cell death receptor-1.